Navigation Links
Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
Date:4/20/2009

that the rate of objective tumor response for the expansion stage of this trial will not be consistent with the objective tumor response experienced in the first stage of the trial and the risk that the standard carboplatin and paclitaxel response rate will not be improved as a result of the combination therapy. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2008 and the quarterly report on Form 10-Q for the quarter ended January 31, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

    Contacts:
    GendeLLindheim BioCom Partners
    Investors                                   Media
    info@peregrineinc.com                       Barbara Lindheim
    (800) 987-8256               
'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
2. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
3. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
4. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
5. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
6. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
10. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
11. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)...  Eli Lilly and Company (NYSE: LLY ) announced ... for up to $1.6 billion aggregate principal amount (the "tender ... billion in aggregate principal amount of the notes listed in ... on or prior to 5:00 p.m., New York ... tender date for the offer. The table ...
(Date:5/27/2015)... , May 27, 2015 ... announced the addition of the  "2015 Strategies ...  report to their offering. ... pertaining to the UK NAT laboratory practice, ... social and technological trends with significant market ...
(Date:5/27/2015)... 2015 Research and ... of the  "North America Mammography Market - ...  report to their offering. ... a detailed type of imaging that customs ... A mammography exam, called a mammogram, is ...
Breaking Medicine Technology:Lilly Announces the Early Results of Its Cash Tender Offer 2Lilly Announces the Early Results of Its Cash Tender Offer 3Lilly Announces the Early Results of Its Cash Tender Offer 4Lilly Announces the Early Results of Its Cash Tender Offer 5North America Mammography Market - Growth, Trends And Forecasts (2014 - 2019) 2
(Date:5/28/2015)... (PRWEB) May 28, 2015 First ... freestanding emergency rooms in the United States, announced that ... new Denver – Green Valley Ranch facility. , ... increased access to the highest quality emergency medical care ... Valley Ranch facility,” said Dr. James M. Muzzarelli, Executive ...
(Date:5/28/2015)... SpendWell Health, an e-commerce marketplace for ... named a “Cool Vendor” by Gartner in the April ... Payers, 2015 by Jeff Cribbs, Constance Sjoquist, Robert ... vendors, products and services in health care technology—which serve ... care payer market. , SpendWell’s solution delivers the ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Peggy J. Lynam, ... Delegate to the American Physical Therapy Association House of Delegates ... Delegation at their Delegate Assembly. This will be her ... Delegates serves as coordinator and principle spokesperson for the Chapter ... Board of Directors or Delegate Assembly may direct the Chief ...
(Date:5/27/2015)... Riverdale, NJ (PRWEB) May 28, 2015 Throughout ... a study site for research comparing the validity and reliability ... Dr. Preeti Nair, P.T., Ph.D., Associate Professor in the ... principle investigator for the study. , The Shaw Gait Assessment ... $30,000 piece of equipment. The GaitRite is considered the ...
(Date:5/27/2015)... StatRad, a leading provider of cloud-based medical ... Mr. Chris E. Hafey as its new Chief Technology ... of leading new development projects and has extensive experience ... served as the Chief Technology Officer for OnPoint Medical ... for Vital Images. , "I am very excited to ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room to Open New Facility in Denver, Colorado 2Health News:SpendWell Named a “Cool Vendor” by Gartner 2Health News:SpendWell Named a “Cool Vendor” by Gartner 3Health News:SpendWell Named a “Cool Vendor” by Gartner 4Health News:Push to Walk Partners with Seton Hall University for Study 2Health News:StatRad Introduces Mr. Chris E. Hafey as Chief Technology Officer, and the Release of its Advanced Pure HTML5 DICOM Image Uploader 2
... ... who has been providing an invaluable service to consumers who are overwhelmed with ... a high rating by the BBB (Better Business Bureau).,New York, NY (PRWEB) ... and debt relief company, has become a proud member of the TASC (The ...
... Boston, Mass. About 40 percent of children and up ... leukemia (AML) will have a relapse. In recent years, doctors ... stem cells, endlessly replicating cancer cells that generate the immature ... cancer treatments. Now, researchers at Children,s Hospital Boston have found ...
... ... or capacity for change, in the neural circuitry of the visual cortex of juvenile mice. The ... human brain that would allow for the repair of neural circuits following injury or disease. ... San Francisco, CA (Vocus) March ...
... as lymph nodes, cancer can evade detection, researchers find ... from Switzerland provides insight into how tumors remain undetected ... , "The tumor tricks the body into thinking it ... the Laboratory of Lymphatic and Cancer Bioengineering, said in ...
... This press release is available in French ... have discovered a previously hidden channel to attack leukemia and ... the Journal of Biological Chemistry . The findings from ... change the way doctors treat cancer patients. "We found ...
... ... for cloud hosting technology, 2. What is web hosting, 3. What is cloud server web hosting, ... 6. Where you can get good cloud server web hosting , ... Burlington, VT (PRWEB) March 24, 2010 -- On March 25th 2010 Omega ...
Cached Medicine News:Health News:National Debt Relief Group Celebrates Proud Membership with TASC (The Association for Settlement Companies) 2Health News:Targeting cell pathway may prevent relapse of leukemia 2Health News:Targeting cell pathway may prevent relapse of leukemia 3Health News:New Period of Brain ‘Plasticity' Created with Transplanted Embryonic Cells 2Health News:New Period of Brain ‘Plasticity' Created with Transplanted Embryonic Cells 3Health News:New Period of Brain ‘Plasticity' Created with Transplanted Embryonic Cells 4Health News:New Period of Brain ‘Plasticity' Created with Transplanted Embryonic Cells 5Health News:New gateway to treat leukemia and other cancers 2Health News:Launching New Cloud Server Technologies on Website Hosting and Much Cheaper Web Hosting 2Health News:Launching New Cloud Server Technologies on Website Hosting and Much Cheaper Web Hosting 3Health News:Launching New Cloud Server Technologies on Website Hosting and Much Cheaper Web Hosting 4Health News:Launching New Cloud Server Technologies on Website Hosting and Much Cheaper Web Hosting 5Health News:Launching New Cloud Server Technologies on Website Hosting and Much Cheaper Web Hosting 6
Inquire...
Supercassette quick release holder for the 8000 Series sliding microtome to allow for the use of wax supercassettes, 75x52x19 mm....
... 5040 microtome is of rotary retracting, self-lubricating design ... cutting arm. Its robust construction makes it accurate ... hinges means that all lateral motion is controlled ... be experienced in other, lesser designs which can ...
Spare fuse set...
Medicine Products: